JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Начало・Списък с акции・Denali Therapeutics Inc

Denali Therapeutics Inc

Затворен

СекторЗдравеопазване

19.85 2.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.67

Максимум

19.97

Ключови измерители
By Trading Economics
Приходи	-1.6M -129M
Служители	503
EBITDA	8.9M -125M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+82.54% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	5.6K 3.3B
Предишно отваряне	17.74
Предишно затваряне	19.85

Настроения в новините

By Acuity

50%

141 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

13.355 / 16.44 Подкрепа & съпротива

Denali Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Major Central Bank -2-

24.04.2026 г., 19:19 ч. UTC

Придобивния, сливания и поглъщания

Intertek Group Rejects EQT's Revised Offer

26.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26.04.2026 г., 23:44 ч. UTC

Печалби

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26.04.2026 г., 23:44 ч. UTC

Печалби

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls Amid Dollar's Strength -- Market Talk

26.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24.04.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Scoring the Cook Era -- Barrons.com

24.04.2026 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

24.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:09 ч. UTC

Печалби

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24.04.2026 г., 19:48 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24.04.2026 г., 19:22 ч. UTC

Печалби

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24.04.2026 г., 19:06 ч. UTC

Печалби

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24.04.2026 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24.04.2026 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24.04.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

Intertek Rejects Revised EQT Offer

24.04.2026 г., 18:12 ч. UTC

Пазарно говорене

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24.04.2026 г., 18:06 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24.04.2026 г., 17:42 ч. UTC

Печалби

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Печалби

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Denali Therapeutics Inc Прогноза

Ценова цел

By TipRanks

82.54% нагоре

12-месечна прогноза

Среден 36.27 USD 82.54%

Висок 42 USD

Нисък 30 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Denali Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Denali Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

13.355 / 16.44Подкрепа & съпротива

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Настроение

By Acuity

141 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.